Reported results
- Lipocine reported total revenue of $2,290,072 for the quarter ended September 30, 2026, compared to $114,574 for the quarter ended September 30, 2025.
- Net loss attributable to common shareholders was $666,192, or $(0.08) per diluted share, for the quarter ended September 30, 2026, compared to a net loss of $3,186,832, or $(0.59) per diluted share, for the quarter ended September 30, 2025.
- Research and development expenses were $2,070,033 for the quarter ended September 30, 2026, compared to $2,707,777 for the quarter ended September 30, 2025.
- General and administrative expenses were $1,088,564 for the quarter ended September 30, 2026, compared to $767,837 for the quarter ended September 30, 2025.
- As of September 30, 2026, Lipocine had $21.5 million of unrestricted cash, cash equivalents and marketable investment securities.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
